These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2349611)

  • 21. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
    Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
    Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response.
    Marder SR; Midha KK; Van Putten T; Aravagiri M; Hawes EM; Hubbard JW; McKay G; Mintz J
    Br J Psychiatry; 1991 May; 158():658-65. PubMed ID: 1860020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioimmunoassay for the 7-hydroxy metabolite of trifluoperazine and its application to a kinetic study in human volunteers.
    Aravagiri M; Hawes EM; Midha KK
    J Pharm Sci; 1985 Nov; 74(11):1196-202. PubMed ID: 4087181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection.
    Glazer WM; Friedhoff LT; Marder SR; Brown WA
    Schizophr Res; 1992 Dec; 8(2):111-7. PubMed ID: 1457388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
    Wiles DH; McCreadie RG; Whitehead A
    Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitive method for the simultaneous measurement of fluphenazine decanoate and fluphenazine in plasma by high-performance liquid chromatography with coulometric detection.
    Luo JP; Hubbard JW; Midha KK
    J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(2):303-8. PubMed ID: 9061468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients.
    McKane JP; Robinson AD; Wiles DH; McCreadie RG; Stirling GS
    Br J Psychiatry; 1987 Sep; 151():333-6. PubMed ID: 3322467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and application of a specific and sensitive radioimmunoassay for trihexyphenidyl to a pharmacokinetic study in humans.
    He H; McKay G; Wirshing B; Midha KK
    J Pharm Sci; 1995 May; 84(5):561-7. PubMed ID: 7658345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of fluphenazine, related phenothiazine drugs and metabolites by combined high-performance liquid chromatography and radioimmunoassay.
    Goldstein SA; Van Vunakis H
    J Pharmacol Exp Ther; 1981 Apr; 217(1):36-43. PubMed ID: 6110775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on the mechanism of absorption of depot neuroleptics: fluphenazine decanoate in sesame oil.
    Luo JP; Hubbard JW; Midha KK
    Pharm Res; 1997 Aug; 14(8):1079-84. PubMed ID: 9279892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methods for study of fluphenazine kinetics in man.
    Whelpton R; Curry SH
    J Pharm Pharmacol; 1976 Dec; 28(12):869-73. PubMed ID: 12260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.
    Norman TR; Marriott PF; Kimber NM; Burrows GD
    Int Clin Psychopharmacol; 1987 Oct; 2(4):299-305. PubMed ID: 3693869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients.
    Altamura AC; Curry SH; Montgomery S; Wiles DH
    Psychopharmacology (Berl); 1985; 87(1):30-3. PubMed ID: 3933035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate.
    Wiles D; Franklin M; Dencker SJ; Johansson R; Lundin L; Malm U
    Psychopharmacology (Berl); 1980; 71(2):131-6. PubMed ID: 6777812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioimmunoassay for a new phenothiazine derivative and its application.
    Rásky K; Losonczy S; Pátfalusi M
    Acta Physiol Hung; 1992; 79(1):103-11. PubMed ID: 1363169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of the depot antipsychotics.
    Jann MW; Ereshefsky L; Saklad SR
    Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
    Soni SD; Wiles D; Schiff AA; Bamrah JS
    Br J Psychiatry; 1988 Sep; 153():382-4. PubMed ID: 3250675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma fluphenazine levels in patients receiving two doses of fluphenazine decanoate.
    Marder SR; Hubbard JW; Van Putten T; Hawes EM; McKay G; Mintz J; May PR; Midha KK
    Psychopharmacol Bull; 1986; 22(1):264-6. PubMed ID: 3726072
    [No Abstract]   [Full Text] [Related]  

  • 40. Persistence of fluphenazine in plasma after decanoate withdrawal.
    Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
    J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.